Severe GI dysmotility due to scleroderma remains refractory to most therapies. The rationale for recommending rituximab (RTX) in this setting is based on its use in rare cases of autoimmune gastrointestinal dysmotility syndrome (AGID) that appear to have a paraneoplastic basis. There are scattered c...

I agree with @Simon, that it is unlikely that rituximab will help in scleroderma bowel which is actually thought to be from ischemic changes to nerves causing the dysmotility. That being said, there have been a few hints of an antibody-mediated problem with response to IVIG, but not replicated. Is i...